Sugi Predict

Sugi Predict / Compounds / SCHEMBL832518

SCHEMBL832518

SCHEMBL832518

Cc1cc2c(-c3ccc[nH]c3=O)c(C(=O)NS(=O)(=O)c3ccccc3)n(Cc3cc4ccccc4nc3Cl)c2cc1F

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C8 P10632 1/20 0.79
▸ KMT2A Q03164 8/20 0.39
▸ MCL1 Q07820 4/20 0.35
▸ EGFR P00533 1/20 0.35
▸ MEN1 O00255 2/20 0.34
▸ RCE1 Q9Y256 1/20 0.34
▸ AGTR2 P50052 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ GRIN2D O15399 1/20 0.34
▸ GRIN3B O60391 1/20 0.34
▸ GRIK1 P39086 1/20 0.34
▸ GRIA1 P42261 1/20 0.34
▸ GRIA2 P42262 1/20 0.34
▸ GRIA3 P42263 1/20 0.34
▸ GRIA4 P48058 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2A Q12879 1/20 0.34
▸ GRIK2 Q13002 1/20 0.34
▸ GRIK3 Q13003 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL832172 0.90 CYP2C8 (0.76) CYP2C8KMT2AMEN1RCE1
SCHEMBL831646 0.89 CYP2C8 (0.74) CYP2C8KMT2AMEN1RCE1FAAH
SCHEMBL12665480 0.88 CYP2C8 (1.00) CYP2C8KMT2AMEN1RCE1FAAH
SCHEMBL8859155 0.88 CYP2C8 (0.68) CYP2C8KMT2AMEN1RCE1
SCHEMBL12665818 0.87 CYP2C8 (0.88) CYP2C8KMT2AMEN1RCE1FAAH
SCHEMBL12665473 0.86 CYP2C8 (0.84) CYP2C8KMT2AMEN1RCE1FAAH
SCHEMBL12665636 0.86 CYP2C8 (0.78) CYP2C8KMT2AMEN1RCE1FAAH
SCHEMBL832432 0.86 CYP2C8 (0.69) CYP2C8KMT2AMCL1MEN1RCE1
SCHEMBL832443 0.85 CYP2C8 (0.76) CYP2C8KMT2AMEN1RCE1FAAH
SCHEMBL832851 0.84 CYP2C8 (0.66) CYP2C8KMT2AMEN1RCE1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2197842-B1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORP (US) 2012-05-23 — — EP disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 — — US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 — — US disclosed
WO-2009032116-A1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORPORATION (US) 2009-03-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885KMT2A 321/4885MCL1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.